

DAFTAR PUSTAKA

1. Guo YR, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. *Mil Med Res.* 2020;7(1):1-10
2. Kementrian Kesehatan Republik Indonesia/Kementrian Kesehatan RI. Pencegahan pengendalian COVID-19. *Kemenkes RI.* 2019;4:1-214.
3. Kementrian Kesehatan Republik Indonesia. Infeksi emerging. *Kemenkes RI.* 2022.
4. World Health Organization. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. *WHO.* 2021;1-5.
5. Kurniawan E. Info Covid-19 Sumbar, Sabtu 12 Desember 2020. *Portal Resmi Provinsi Sumatera Barat.* 2020.
6. Kementrian Kesehatan Republik Indonesia. Covid dalam angka per 12 Desember 2020. *Kemenkes RI.* 2020.
7. Nugraha MD, Trisyani Y, Mirwanti R. Analisis faktor risiko kematian akibat infeksi COVID-19. *Jurnal Ilmu Kesehatan Bhakti Husada: Health Science Journal.* 2021;12(2):204-14.
8. Pietrobbon AJ, Teixeira FME, Sato MN. Immunosenescence and inflammaging: risk factors of severe COVID-19 in older people. *Front Immunol.* 2020;11:579220.
9. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. *Clinical Rheumatology.* 2020;39(7):2085-94.
10. Sharifi N, Ryan CJ, Sharifi N, Ryan CJ. Androgen hazards with COVID-19. *Endocrine Related Cancer.* 2020;27(6):1-3.
11. Dorland WA, Newman. Kamus Kedokteran Dorland. *Buku kedokteran EGC.* 2010;31.
12. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. *JAMA.* 2020;323(13):1239-42
13. Zhang J, Yu M, Tong S, Liu LY, Tang LV. Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. *J Clin Virol.* 2020;127:104392.
14. Satuan Tugas Penanganan COVID-19. Pedoman Perubahan Perilaku Penanganan Covid-19. *Satgas Penanganan COVID-19.* 2020;1-60.
15. Satuan Tugas Penanganan COVID-19. Peta Sebaran COVID19. *Satgas Penanganan COVID-19.* 2022;1.
16. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-62.
17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061-9.
18. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev.* 2020;36(7):1-9.
19. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC.

- Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA*. 2020;324(8):782-793.
20. Sahin AR. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. *Eurasian J Med Oncol*. 2020;4(1):1-7.
 21. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733.
 22. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). *StatPearls. Treasure Island (FL): StatPearls*. 2022. [Cited 2022 February 25], Available from: doi: 10.1056/NEJMoa2001017
 23. Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. *Trends Immunol*. 2020;41(5):355-359.
 24. Li W, Moore MJ, Vasllieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*. 2003;426(6965):450-4.
 25. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. *PLoS Pathog*. 2018;14(8):1007236.
 26. Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? potential long-term health consequences. *Crit Rev Clin Lab Sci*. 2021;58(5):297-310.
 27. World Health Organization. COVID-19 weekly epidemiological update. *WHO*. 2021;(58):1-23.
 28. Kementerian Kesehatan Republik Indonesia. Analisis Data COVID-19 Indonesia. *Kemendes RI*. 2022.
 29. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. *Int J Oral Sci*. 2020;12(1):1-5.
 30. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. *Nat Rev Microbiol*. 2016;14(8):523-34.
 31. Susilo A, Rumende CM, Pitoyo ACW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus disease 2019: tinjauan literatur terkini. *Jurnal Penyakit Dalam Indonesia*. 2020;7(1):45-67.
 32. Cen Y, Chen X, Shen Y, Zhang XH, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019- a multi-centre observational study. *Clin Microbiol Infect*. 2020;26(9):1242-7.
 33. Rahman FS, Heriyani F, Nurrasyidah I, Noor MS, Washilah S. Hubungan tingkat pendidikan dan pekerjaan dengan kejadian Covid-19 di Puskesmas Pemurus Dalam Kota Banjarmasin. *Homeostasis*. 2022;5(1):1-10.
 34. Mutambudzi M, Niedwiedz C, Macdonald EB, Leyland A, Mair F, Anderson J, et al. Occupation and risk of severe COVID-19: Prospective cohort study of 120 075 UK Biobank participants. *Occup Environ Med*. 2021;78(5):307-14.
 35. Juwita SS, Anggraini D, Kurniawati D. Gambaran Karakteristik Pasien Covid-19 Di Rumah Sakit Otak Dr. Mohammad Hatta Bukittinggi. *Afiyah*.

- 2022;9(1):1-5
36. Ye C, Zhang S, Zhang X, Cai H, Gu J, Lian J, et al. Impact of comorbidities on patients with COVID-19: a large retrospective study in Zhejiang, China. *J Med Virol*. 2020;92:2821–9.
 37. Burhan E, Susanto AD, Nasution SA, Ginanjar E, Pitoyo CW, Susilo A, et al. Pedoman Tatalaksana COVID-19. *PDPI, PERKI, PAPDI, PERDATIN, IDAI*. 2020;1:50.
 38. Jiang N, Liu YN, Bao J, Li R, Ni WT, Tan XY, et al. Clinical features and risk factors associated with severe COVID-19 patients in China. *Chin Med J (Engl)*. 2021;134(8):944–53.
 39. Kementerian Kesehatan Republik Indonesia. Pedoman Pencegahan dan Pengendalian COVID-19. *Kemendes*. 2020;1(4):1–125.
 40. Kulkarni S, Jenner BL, Wilkinson I. COVID-19 and hypertension. *J Renin Angiotensin Aldosterone Syst*. 2020;21(2):1470320320927851.
 41. Kario K, Morisawa Y, Sukonthasarn A, Turana Y, Chia YC, Park S, et al. COVID-19 and hypertension-evidence and practical management: guidance from the HOPE Asia Network. *J Clin Hypertens (Greenwich)*. 2020;22(7):1109-1119.
 42. Pititto B A, Ferreira SRG. Diabetes and covid-19: more than the sum of two morbidities. *Rev Saude Publica*. 2020;54:54.
 43. Mullen B. COVID-19 clinical guidance for the cardiovascular care team. *J Am Coll Cardiol*. 2020;44:1-4.
 44. Scheen AJ. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations. *Diabetes Metab*. 2021;47(2):101213.
 45. Abdi A, Jalilian M, Sarbarzeh PA, Vlasisavljevic Z. Diabetes and COVID-19: a systematic review on the current evidences. *Diabetes Res Clin Pract*. 2020;166:108347.
 46. Akhmerov A, Marbán E. COVID-19 and the heart. *Circ Res*. 2020;126(10):1443-1455.
 47. Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. *JAMA Cardiol*. 2020;5(7):751–3.
 48. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–506.
 49. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural Studies of SARS coronavirus. *J Virol*. 2020;94(7):e00127-20.
 50. Kang DH, Weaver MT, Park NJ, Smith B, McArdle T, Carpenter J. Significant impairment in immune recovery after cancer treatment. *Nurs Res*. 2009;58(2):105–14.
 51. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. *Cancer Discov*. 2020;10(6):783-91
 52. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: deleterious impact on infected patients. *J Infect Public Health*. 2020;12:1833–9.
 53. D’Marco L, Puchades MJ, Romero-Parra M, Gimenez-Civera E, Soler MJ,

- Ortiz A, et al. Coronavirus disease 2019 in chronic kidney disease. *Clin Kidney J.* 2020;13(3):297–306.
54. Chen YT, Shao SC, Lai EC, Hung MJ, Chen YC. Mortality rate of acute kidney injury in SARS, MERS, and COVID-19 infection: a systematic review and meta-analysis. *Crit Care.* 2020;24(1):439.
 55. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. *Int Urol Nephrol.* 2020;52(6):1193-1194.
 56. Rahayu LA, Admiyanti JC, Khalda YI, Adha FR, Agistany NFF. Hipertensi, diabetes melitus dan obesitas sebagai faktor komorbiditas utama terhadap mortalitas pasien covid-19 : sebuah studi literatur. *Jurnal Ilmiah Mahasiswa Kedokteran Indonesia.* 2021;9:90–7.
 57. Czernichow S, Beeker N, Rives-Lange C, Guerot E, Diehl JL, Katsahian S, et al. Obesity doubles mortality in patients hospitalized for severe acute respiratory syndrome coronavirus 2 in Paris Hospitals, France: a cohort study on 5,795 patients. *Obesity.* 2020;12:2282–9.
 58. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395(10223):507–13.
 59. Dufour JF, Marjot T, Becchetti C, Tilg H. COVID-19 and liver disease. *Gut.* 2022;71(11):2350-2362.
 60. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: a hospital-based retrospective cohort study. *Lancet Reg Heal - West Pacific.* 2021;9:10018.
 61. Hughes-Visentin A, Paul ABM. Asthma and COVID-19: what do we know now. *Clin Med Insights Circ Respir Pulm Med.* 2020;14:1-7.
 62. Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. *PLoS One.* 2021;16(10):1–18.
 63. Wilkinson RJ. Tuberculosis and type 2 diabetes mellitus: an inflammatory danger signal in the time of coronavirus disease 2019. *Clin Infect Dis.* 2021;72(1):79–81.
 64. Irfani TH, Siburian R, Nabila R, Umar TP. Tuberculosis and coronavirus disease 2019 (COVID-19) from a clinical perspective: a systematic review. *Medeni Med J.* 2020;35(4):338–43.
 65. Madhi, Shabir, Blumberg, Hellen L, Helen R. ASSAF Statement on the Implications of the Novel Coronavirus (SARS-CoV-2; COVID-19) in South Africa. *Academy of Science of South Africa (ASSAF).* 2020
 66. Kouhpayeh H, Ansari H. HIV infection and increased risk of COVID-19 mortality: a meta-analysis. *Eur J Transl Myol.* 2021;31(4):1-9
 67. Hakim LN. Urgensi revisi undang-undang tentang kesejahteraan lanjut usia. *Aspir J Masal Sos.* 2020;11(1):43–55.
 68. Departemen Pendidikan Nasional. Undang-Undang Republik Indonesia Nomor 20 Tahun 2003 Tentang Sistem Pendidikan Nasional. *Depdiknas.* 2003;4:147–73.
 69. Wiltshire AH. The meanings of work in a public work scheme in South

- Africa. *Int J Sociol Soc Policy*. 2016;36(1–2):2–17.
70. National Center for Immunization and Respiratory Diseases (NCIRD). Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. *Centers Dis Control Prev*. 2022;1–8. [Cited 2023 January 18], Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html#complete-list-disabilities>
 71. Yulia R, Surabaya U, Herawati F, Surabaya U. Profil Penggunaan Obat pada Pasien Covid -19 di Ruang Isolasi Rumah Sakit X Kabupaten Malang. 2022;11:2870-8
 72. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance - United States. 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(24):759
 73. Wen S, Prasad A, Freeland K, Podury S, Patel J, Subedi R, et al. Clinical characteristics and outcomes of covid-19 in west virginia. *Viruses*. 2021;13(5):1–14.
 74. Das SK. The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). *Indian J Clin Biochem*. 2020;35(4):385–96.
 75. Widjaja JT, Kwee L, Giantara AK, Suabgiyo HA, Edwin C, Putri RL. Karakteristik Pasien COVID-19 Rawat Inap di RS Immanuel Bandung, Indonesia. *J Med Heal*. 2021;3(2):164–75.
 76. Drefahl S, Wallace M, Mussino E, Aradhya S, Kolk M, Brandén M, et al. A population-based cohort study of socio-demographic risk factors for COVID-19 deaths in Sweden. *Nat Commun*. 2020;11(1):1–7.
 77. Upik N, Masrika E, Hasan M, Yusran Y, Buyung S. Karakteristik Pasien COVID -19 di Rumah Sakit Umum Daerah Dr . H . Chasan Boesoerie. *Jumantik*. 2022;7(3):255–65.
 78. Sufiyanto S, Yuniarti S, Andrijono D. Sosialisasi dan Edukasi Penilaian Mandiri terhadap Risiko Penularan COVID-19 melalui InaRISK Personal. *Abdimas J Pengabdian Masy Univ Merdeka Malang*. 2020;5(3):209–19.
 79. Akhtar H, Khalid S, ur Rahman F, Umar M, Ali S, Afridi M, et al. Presenting Characteristics, Comorbidities, and Outcomes among Patients with COVID-19 Hospitalized in Pakistan: Retrospective Observational Study. *JMIR Public Heal Surveill* 2021;7(12):e32203
 80. Parra-Bracamonte GM, Lopez-Villalobos N, Parra-Bracamonte FE. Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico. *Ann Epidemiol*. 2020;52:93-98.
 81. Indriyani N, Sabri YS, Afriani A. Association Between Comorbidities and Outcome of COVID-19 Patients at dr. M. Djamil General Hospital Padang. *Respir Sci*. 2022;3(1):38–50.
 82. Putra IMAA. Hubungan Komorbiditas Terhadap Derajat keparahan Admisi dan Outcome Pasien COVID-19 di Rumah Sakit Bethesda Yogyakarta. *Nuevos Sist Comun e Inf*. 2021;2013–5.